527 Digital spatial profiling of paired tumor biopsies reveals indoleamine 2,3-dioxygenase (IDO)1 as a potential resistance mechanism for a tumor-targeted 4–1BB agonist in patients with solid tumors

• Maurizio Ceppi,
• Bruno Gomes,
• Irina Klaman,
• Marta Canamero,
• Christian Heichinger,
• Tamara Tanos,
• Sabine Wilson,
• Mariana Bustamante,
• Chiahuey Ooi

Affiliations

Maurizio Ceppi

Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland

Bruno Gomes

Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

Irina Klaman

Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany

Marta Canamero

6Roche pRED, Zürich, Switzerland

Christian Heichinger

6Roche pRED, Zürich, Switzerland

Tamara Tanos

6Roche pRED, Zürich, Switzerland

Sabine Wilson

1Roche Innovation Center Basel, Basel, Switzerland

Mariana Bustamante

1Roche Innovation Center Basel, Basel, Switzerland

Chiahuey Ooi

1Roche Innovation Center Basel, Basel, Switzerland